Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …

MYC rearrangements occur in 5% to 10% of diffuse large B-cell lymphomas (DLBCL) and
confer an increased risk to cyclophosphamide, hydroxydaunorubicin, oncovin, and …

The clinical significance of MYC and BCL2 genetic alterations in diffuse large B-cell
lymphoma (DLBCL), apart from translocations, has not been comprehensively investigated …

Purpose Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with
rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC …

Purpose: We have previously shown the prognostic significance of BCL2 expression in the
activated B-cell–like diffuse large B-cell lymphoma (ABC-DLBCL) patients treated with …

Diffuse large B‐cell lymphoma (DLBCL) is a heterogeneous disease and “double‐hit”
DLBCL, with both MYC and BCL 2 translocations has a poor prognosis. In this study, we …

Purpose Diffuse large B-cell lymphoma (DLBCL) includes at least two prognostically
important subtypes (ie, germinal center B-cell–like [GCB] and activated B-cell–like [ABC] …

Purpose To explore the prognostic impact and interdependence of the cell-of-origin (COO)
classification, dual expression (DE) of MYC and BCL2 proteins, and MYC, BCL2, and BCL6 …

Background The role of BCL2 as a predictor of survival in diffuse large B-cell lymphoma
(DLBCL) is controversial. DLBCL is heterogeneous, and the expression of BCL2 is variable …

Diffuse large B-cell lymphoma can be classified by gene expression profiling into germinal
center and activated B-cell subtypes with different prognoses after rituximab-CHOP. The …